Fostriecin | Enzo Life Sciences ALX-380-065-C010 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Fostriecin

catalog :

ALX-380-065-C010

quantity :

10 µg

citations: 10

Reference
Lewy D, Gauss C, Soenen D, Boger D. Fostriecin: chemistry and biology. Curr Med Chem. 2002;9:2005-32 pubmed
de Jong R, Mulder N, Uges D, Sleijfer D, Höppener F, Groen H, et al. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Br J Cancer. 1999;79:882-7 pubmed
Weinbrenner C, Baines C, Liu G, Armstrong S, Ganote C, Walsh A, et al. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation. 1998;98:899-905 pubmed
Walsh A, Cheng A, Honkanen R. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett. 1997;416:230-4 pubmed
de Jong R, de Vries E, Mulder N. Fostriecin: a review of the preclinical data. Anticancer Drugs. 1997;8:413-8 pubmed
Gorczyca W, Bigman K, Mittelman A, Ahmed T, Gong J, Melamed M, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia. 1993;7:659-70 pubmed
Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 1993;53:3186-92 pubmed
Roberge M, Tudan C, Hung S, Harder K, Jirik F, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res. 1994;54:6115-21 pubmed
Stampwala S, Bunge R, Hurley T, Willmer N, Brankiewicz A, Steinman C, et al. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization. J Antibiot (Tokyo). 1983;36:1601-5 pubmed
Tunac J, Graham B, Dobson W. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties. J Antibiot (Tokyo). 1983;36:1595-600 pubmed

product information

Product ID :

ALX-380-065

Catalog Number :

ALX-380-065-C010

Product Name :

Fostriecin

Product Type :

Biochemical

Size :

10 µg

list of Pubmed id :

12369868, 10070885, 9738645, 9373158, 9215602, 8483318, 8319228, 7954457, 6689324, 6689323

Product Description :

Antitumor antibiotic. Catalytic inhibitor of topoisomerase II. Strong protein phosphatase 2A (PP2A) inhibitor (IC50=3.2nM). Weak inhibitor for PP1 (IC50=131µM). No apparent effect on PP2B. The binding site for fostriecin on PP2A is different from that of okadaic acid (see Prod. No. ALX-350-003).

ALTnames :

Phosphotrienin, CI-920

Purity :

≥98% (HPLC)

Storage :

-20°C